Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 1/20 | 0.36 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.34 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 3/20 | 0.32 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | HPGD | P15428 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | MAOB | P27338 | 4/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | ULK1 | O75385 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29903155 | 1.00 | GRM5 (0.36) | GRM5PTPN1CYP1A2CYP2A6MAPT | |
| SCHEMBL29903159 | 0.88 | CYP1A2 (0.35) | GRM5CYP1A2CYP2A6MAPTHPGD | |
| SCHEMBL23409334 | 0.88 | CYP1A2 (0.35) | GRM5CYP1A2CYP2A6MAPTHPGD | |
| SCHEMBL25354684 | 0.88 | MAPT (0.34) | GRM5CYP1A2MAPTLMNAHPGD | |
| SCHEMBL25428945 | 0.84 | CYP1A2 (0.44) | CYP1A2CYP2A6MAPTKMT2A | |
| SCHEMBL22208168 | 0.84 | GRM5 (0.33) | GRM5CYP1A2CYP2A6MAPTHPGD | |
| SCHEMBL29914173 | 0.84 | NPC1 (0.33) | GRM5CYP1A2CYP2A6MAPTKDM4E | |
| SCHEMBL23043033 | 0.84 | NPC1 (0.33) | GRM5CYP1A2CYP2A6MAPTKDM4E | |
| SCHEMBL29418746 | 0.84 | GRM5 (0.33) | GRM5CYP1A2CYP2A6MAPTHPGD | |
| SCHEMBL25824423 | 0.81 | HTR2A (0.33) | GRM5CYP1A2CYP2A6MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230348495-A1 | A COMPOUND HAVING INHIBITORY ACTIVITY AGAINST KRAS G12D MUTATION | ASTEX THERAPEUTICS LIMITED (GB) | 2023-11-02 | — | — | US | disclosed |
| WO-2023141570-A2 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF KRAS | ARVINAS OPERATIONS, INC. (US) | 2023-07-27 | — | — | WO | disclosed |
| WO-2023141570-A2 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF KRAS | ARVINAS OPERATIONS, INC. (US) | 2023-07-27 | — | — | WO | disclosed |
| CN-115003677-A | Compounds having inhibitory activity against KRAS G12D mutation | 大鹏药品工业株式会社 | 2022-09-02 | — | — | CN | disclosed |
| WO-2021106231-A1 | A COMPOUND HAVING INHIBITORY ACTIVITY AGAINST KRAS G12D MUTATION | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2021-06-03 | — | — | WO | disclosed |
| WO-2021107160-A1 | A COMPOUND HAVING INHIBITORY ACTIVITY AGAINST KRAS G12D MUTATION | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2021-06-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230348495-A1 | A COMPOUND HAVING INHIBITORY ACTIVITY AGAINST KRAS G12D MUTATION | KRAS, NRAS, HRAS | GRM5 2999/4885PTPN1 248/4885CYP1A2 4496/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.